Turn Therapeutics (NASDAQ:TTRX) Upgraded at WBB Securities

WBB Securities upgraded shares of Turn Therapeutics (NASDAQ:TTRX) from a sell rating to a hold rating in a research report report published on Friday, Marketbeat reports. WBB Securities currently has $10.00 price target on the stock.

A number of other equities research analysts have also issued reports on TTRX. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a “strong-buy” rating in a research note on Monday, July 20th. Weiss Ratings cut Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Lucid Cap Mkts raised Turn Therapeutics to a “strong-buy” rating in a research note on Thursday, September 24th. Finally, Wall Street Zen cut Turn Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, October 18th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Turn Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

Turn Therapeutics Price Performance

Shares of NASDAQ:TTRX opened at $10.28 on Friday. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. Turn Therapeutics has a 1-year low of $2.57 and a 1-year high of $16.45. The company has a market capitalization of $313.85 million and a P/E ratio of -35.45. The firm’s 50 day simple moving average is $11.64 and its two-hundred day simple moving average is $8.18.

Turn Therapeutics (NASDAQ:TTRX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. Research analysts expect that Turn Therapeutics will post -0.40 EPS for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Ieq Capital LLC bought a new position in shares of Turn Therapeutics during the 2nd quarter valued at about $1,660,000. DDFG Inc grew its position in shares of Turn Therapeutics by 34.9% during the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after purchasing an additional 18,246 shares in the last quarter. Bridgewater Advisors Inc. purchased a new position in shares of Turn Therapeutics during the second quarter valued at about $242,000. Jefferies Financial Group Inc. bought a new stake in shares of Turn Therapeutics in the second quarter worth about $119,000. Finally, BlackRock Inc. bought a new stake in shares of Turn Therapeutics in the second quarter worth about $282,000.

About Turn Therapeutics

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.